Financial toxicity risk among patients undergoing CRS-HIPEC: Study reveals one-third at risk

Researchers conducted a retrospective cohort study on 163 patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) between 2016 and 2022. They found that 31.9% of patients were at risk of financial toxicity, with higher out-of-pocket expenditures and lower income quartiles being significant risk factors. The median out-of-pocket expenditure for at-risk patients was $5000, compared to $3341 for those not at risk. These findings suggest the need for interventions and identification of patients who may benefit from financial support in CRS-HIPEC treatment.